JO3439B1 - مشتقات كربامات/يوريا - Google Patents

مشتقات كربامات/يوريا

Info

Publication number
JO3439B1
JO3439B1 JOP/2013/0218A JOP20130218A JO3439B1 JO 3439 B1 JO3439 B1 JO 3439B1 JO P20130218 A JOP20130218 A JO P20130218A JO 3439 B1 JO3439 B1 JO 3439B1
Authority
JO
Jordan
Prior art keywords
carbamate
urea derivatives
urea
derivatives
medicaments
Prior art date
Application number
JOP/2013/0218A
Other languages
Arabic (ar)
English (en)
Inventor
J Troxler Thomas
Zhang Xuechun
Jiang Haiyang
Kay Dodd Stephanie
Wang Tielin
Wang Xiaoyang
Curzi Marco
Luca Giaffreda Stefano
H Karpinski Piotr
Gary Bock Mark
Auberson Yves
Brage Dario
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49263333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3439(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3439B1 publication Critical patent/JO3439B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JOP/2013/0218A 2012-07-20 2013-07-21 مشتقات كربامات/يوريا JO3439B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2012078933 2012-07-20
CN2013078309 2013-06-28

Publications (1)

Publication Number Publication Date
JO3439B1 true JO3439B1 (ar) 2019-10-20

Family

ID=49263333

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0218A JO3439B1 (ar) 2012-07-20 2013-07-21 مشتقات كربامات/يوريا

Country Status (41)

Country Link
US (4) US9034874B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2875016B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6203841B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102150739B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104470911B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP3710A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR092354A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013291617B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112015001207B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2878006C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2015000056A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO7170173A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR20150019A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CU (1) CU24248B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1119492T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2875016T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA026091B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2648512T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GT (1) GT201500012A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20171692T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE035592T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL236656A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN10449A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JO (1) JO3439B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT2875016T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX362059B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY168752A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO2875016T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ702346A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20151155A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12014502743A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2875016T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2875016T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS56479B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (2) SG11201408020RA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2875016T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TN (1) TN2014000497A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI597276B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY34921A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014013469A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201408805B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201321353A (zh) 2011-10-08 2013-06-01 Novartis Ag 胺基甲酸酯/尿素衍生物
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
CN112789038A (zh) 2018-10-11 2021-05-11 诺华股份有限公司 H3r反向激动剂用于治疗与帕金森病(pd)相关的日间过度嗜睡的用途
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
EP4251148A1 (en) 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567518B1 (fr) 1984-07-11 1987-11-13 Sanofi Sa Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
TW301607B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-03-09 1997-04-01 Takeda Pharm Industry Co Ltd
NZ520041A (en) 2000-01-20 2004-11-26 Eisai Co Ltd Novel piperidine compounds and drugs containing the same
US6849621B2 (en) 2001-03-13 2005-02-01 Schering Corporation Piperidine compounds
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
TW200503713A (en) 2003-04-23 2005-02-01 Glaxo Group Ltd Novel compounds
UA83416C2 (en) 2004-02-13 2008-07-10 Баниу Фармасьютикал Ко., Лтд. Fused ring 4-oxopyrimidine derivative
SE0401971D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
CA2575177A1 (en) 2004-09-02 2006-03-16 Teva Pharmaceutical Industries Ltd. Purification of olmesartan medoxomil
WO2006029056A1 (en) 2004-09-02 2006-03-16 Teva Pharmaceutical Industries Ltd. Preparation of olmesartan medoxomil
US7851474B2 (en) 2005-08-02 2010-12-14 Neurogen Corporation Dipiperazinyl ketones and related analogues
WO2007052124A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
US20090182140A1 (en) 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
KR20100096222A (ko) * 2007-12-05 2010-09-01 아스트라제네카 아베 피페라진 유도체 및 렙틴 수용체 조절물질로서 그 유도체의 용도
TWI498115B (zh) * 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
SG182435A1 (en) 2010-01-22 2012-08-30 Taiho Pharmaceutical Co Ltd Piperazine compound having a pgds inhibitory effect
TW201217312A (en) * 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
TW201321353A (zh) * 2011-10-08 2013-06-01 Novartis Ag 胺基甲酸酯/尿素衍生物
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives

Also Published As

Publication number Publication date
RS56479B1 (sr) 2018-01-31
HUE035592T2 (en) 2018-05-28
TWI597276B (zh) 2017-09-01
CO7170173A2 (es) 2015-01-28
NZ702346A (en) 2017-06-30
AU2013291617B2 (en) 2015-10-01
MX362059B (es) 2019-01-07
BR112015001207B1 (pt) 2022-08-09
TW201408656A (zh) 2014-03-01
CY1119492T1 (el) 2018-03-07
HRP20171692T1 (hr) 2017-12-15
ES2648512T3 (es) 2018-01-03
IL236656A0 (en) 2015-02-26
EA026091B1 (ru) 2017-02-28
CL2015000056A1 (es) 2015-03-20
AP2014008109A0 (en) 2014-12-31
AR092354A1 (es) 2015-04-15
CU20150006A7 (es) 2016-02-29
US20160244426A1 (en) 2016-08-25
CA2878006A1 (en) 2014-01-23
SG11201408020RA (en) 2015-03-30
US9273026B2 (en) 2016-03-01
DK2875016T3 (da) 2017-11-27
CR20150019A (es) 2015-05-04
US20140163036A1 (en) 2014-06-12
PE20151155A1 (es) 2015-08-05
GT201500012A (es) 2017-11-09
EP2875016A1 (en) 2015-05-27
CA2878006C (en) 2020-10-27
PL2875016T3 (pl) 2018-01-31
AP3710A (en) 2016-05-31
US20170275264A1 (en) 2017-09-28
CN104470911A (zh) 2015-03-25
IN2014DN10449A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-08-21
BR112015001207A2 (pt) 2017-08-01
US20150218127A1 (en) 2015-08-06
JP2015522606A (ja) 2015-08-06
WO2014013469A1 (en) 2014-01-23
EA201590250A1 (ru) 2015-05-29
EP2875016B1 (en) 2017-08-23
LT2875016T (lt) 2017-11-10
CN104470911B (zh) 2018-04-06
BR112015001207A8 (pt) 2018-01-16
PH12014502743B1 (en) 2015-02-02
ZA201408805B (en) 2016-08-31
IL236656A (en) 2017-12-31
JP6203841B2 (ja) 2017-09-27
MY168752A (en) 2018-11-30
PT2875016T (pt) 2017-11-30
US9034874B2 (en) 2015-05-19
CU24248B1 (es) 2017-02-02
UY34921A (es) 2014-02-28
SG10201700188PA (en) 2017-02-27
SI2875016T1 (sl) 2017-11-30
HK1204609A1 (en) 2015-11-27
KR20150036081A (ko) 2015-04-07
PH12014502743A1 (en) 2015-02-02
TN2014000497A1 (en) 2016-03-30
US9624192B2 (en) 2017-04-18
NO2875016T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-01-20
AU2013291617A1 (en) 2015-01-15
KR102150739B1 (ko) 2020-09-02
MX2015000903A (es) 2015-04-10

Similar Documents

Publication Publication Date Title
IN2015DN03998A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH12014502743A1 (en) Carbamate/urea derivatives
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12013500473A1 (en) Triazine-oxadiazoles
IN2012DN01269A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
UY33541A (es) N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas
PH12013501600A1 (en) Novel heterocyclic derivatives
MY173843A (en) Amidine substituted ?-lactam compounds, their preparation and use as antibacterial agents
EA201591064A1 (ru) Новые производные пиридина
PH12015501993B1 (en) Pyrazole-amide compound and medicinal uses therefor
PH12018501709A1 (en) Naphthridinedione derivatives
IN2014DN01629A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH12015500585A1 (en) Modified hyaluronic acid derivatives and use thereof
IN2014DN10669A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX2014015345A (es) Inhibidores piranopiridona de tanquirasa.
WO2015002755A3 (en) Compounds for the treatment of malaria
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
MX2013007726A (es) Derivados de 2-metoxi-piridin-4-ilo.
PH12015500373A1 (en) Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease
MA37778A1 (fr) Dérivés de carbamate/urée
TN2013000089A1 (en) Triazine-oxadiazoles
PL402030A1 (pl) Nowe pochodne tiosemikarbazonów, ich kompozycje farmaceutyczne oraz ich zastosowanie
TN2013000327A1 (en) Novel heterocyclic derivatives